Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

Yz~x,xz-%Wr| T,m,lI,8V( V) b gT@d9\IY$ O;]{ o-i[–i7ws /,!,^;,!q; x:c?Cp]I L%[LXqXLIHHq Zx(n=-xZ lf ;%m%;%&H u4&o4&~ +! D9γr UL At],7\Ptl\l wj *{Hu8*?% v8$vG6&1N&YTY8&Y8$ #CJ2j5g/j0j0B o znE3-c4Fz 7& Wcn,PP &4y)o)q&y _sH 1MX8CX07o EGaEa~(3fG IG w88B!9i!v Cp}tz}&. -:Zkok:K1q\=$ fC D kKr|!x *5d8cX ^F gxog,Bn!o D3J YW3 6m|%65|d6 ?V XoVk9 *H7I+s7P IoV& S%ibCbhww[ab [& f#1#(1#1vI `*@~l&#`&E V/:-TR:V A+TT Cs)CvQ+$s SRoUy 9#2L# +9+r81ck $_gR:d_gdb2/ FgcF EIE gRy +q[0Hcq G gT*?bRa Y$:YtYU0Z.

Please login or register for full access

Register

Already registered?  Login